Joint conference on the impact of EU legislation on therapeutic advance

Research output: Contribution to journalArticleResearchpeer review

Authors

  • Nikolaus Forgó
  • Martin Hildebrandt

Research Organisations

External Research Organisations

  • Technical University of Munich (TUM)
View graph of relations

Details

Original languageEnglish
Pages (from-to)1444-1448
Number of pages5
JournalCYTOTHERAPY
Volume15
Issue number12
Early online date28 Aug 2013
Publication statusPublished - Dec 2013

Abstract

On October 11, 2012, two FP7-funded Research Consortia, CONTRACT (Consent in a Trial and Care Environment) and Academic GMP, held a Joint Conference in Brussels entitled "The Impact of EU Legislation on Therapeutic Advance." Academic researchers including stem cell transplant physicians and cell therapy specialists, legal advocates and representatives from industry, regulatory authorities and patient advocacy groups met with members of the European Parliament and the European Commission. This article summarizes important points of discussion and detailed proposals for improvement.

Keywords

    ATMP, Clinical trial, European Union, Informed consent

ASJC Scopus subject areas

Sustainable Development Goals

Cite this

Joint conference on the impact of EU legislation on therapeutic advance. / Forgó, Nikolaus; Hildebrandt, Martin.
In: CYTOTHERAPY, Vol. 15, No. 12, 12.2013, p. 1444-1448.

Research output: Contribution to journalArticleResearchpeer review

Forgó N, Hildebrandt M. Joint conference on the impact of EU legislation on therapeutic advance. CYTOTHERAPY. 2013 Dec;15(12):1444-1448. Epub 2013 Aug 28. doi: 10.1016/j.jcyt.2013.06.011
Forgó, Nikolaus ; Hildebrandt, Martin. / Joint conference on the impact of EU legislation on therapeutic advance. In: CYTOTHERAPY. 2013 ; Vol. 15, No. 12. pp. 1444-1448.
Download
@article{10da8aae0b6349cebadffe2601b92e79,
title = "Joint conference on the impact of EU legislation on therapeutic advance",
abstract = "On October 11, 2012, two FP7-funded Research Consortia, CONTRACT (Consent in a Trial and Care Environment) and Academic GMP, held a Joint Conference in Brussels entitled {"}The Impact of EU Legislation on Therapeutic Advance.{"} Academic researchers including stem cell transplant physicians and cell therapy specialists, legal advocates and representatives from industry, regulatory authorities and patient advocacy groups met with members of the European Parliament and the European Commission. This article summarizes important points of discussion and detailed proposals for improvement.",
keywords = "ATMP, Clinical trial, European Union, Informed consent",
author = "Nikolaus Forg{\'o} and Martin Hildebrandt",
note = "Funding Information: The research presented in this article has received funding from the European Union's Seventh Framework Programme ( FP7/2007-2013 ) under grant agreements No. 260773 (Academic GMP) and 261412 (CONTRACT). ",
year = "2013",
month = dec,
doi = "10.1016/j.jcyt.2013.06.011",
language = "English",
volume = "15",
pages = "1444--1448",
journal = "CYTOTHERAPY",
issn = "1465-3249",
publisher = "Elsevier Inc.",
number = "12",

}

Download

TY - JOUR

T1 - Joint conference on the impact of EU legislation on therapeutic advance

AU - Forgó, Nikolaus

AU - Hildebrandt, Martin

N1 - Funding Information: The research presented in this article has received funding from the European Union's Seventh Framework Programme ( FP7/2007-2013 ) under grant agreements No. 260773 (Academic GMP) and 261412 (CONTRACT).

PY - 2013/12

Y1 - 2013/12

N2 - On October 11, 2012, two FP7-funded Research Consortia, CONTRACT (Consent in a Trial and Care Environment) and Academic GMP, held a Joint Conference in Brussels entitled "The Impact of EU Legislation on Therapeutic Advance." Academic researchers including stem cell transplant physicians and cell therapy specialists, legal advocates and representatives from industry, regulatory authorities and patient advocacy groups met with members of the European Parliament and the European Commission. This article summarizes important points of discussion and detailed proposals for improvement.

AB - On October 11, 2012, two FP7-funded Research Consortia, CONTRACT (Consent in a Trial and Care Environment) and Academic GMP, held a Joint Conference in Brussels entitled "The Impact of EU Legislation on Therapeutic Advance." Academic researchers including stem cell transplant physicians and cell therapy specialists, legal advocates and representatives from industry, regulatory authorities and patient advocacy groups met with members of the European Parliament and the European Commission. This article summarizes important points of discussion and detailed proposals for improvement.

KW - ATMP

KW - Clinical trial

KW - European Union

KW - Informed consent

UR - http://www.scopus.com/inward/record.url?scp=84887115967&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2013.06.011

DO - 10.1016/j.jcyt.2013.06.011

M3 - Article

C2 - 23992669

AN - SCOPUS:84887115967

VL - 15

SP - 1444

EP - 1448

JO - CYTOTHERAPY

JF - CYTOTHERAPY

SN - 1465-3249

IS - 12

ER -